Standard Operating Procedure for Handling Urgent Labeling Updates Following New Risks
| Department | Regulatory Affairs |
| SOP No. | RA/2026/761 |
| Supersedes | NA |
| Page No. | 1 of X |
| Issue Date | 16/04/2026 |
| Effective Date | 16/04/2026 |
| Review Date | 16/04/2028 |
Purpose
This SOP establishes the standardized process to manage and implement urgent updates to product labeling arising from newly identified risks. The objective is to ensure timely dissemination and regulatory compliance of updated labeling information to protect patient safety, maintain product integrity, and meet regulatory requirements across all applicable products and markets.
Scope
This procedure applies to all labeling updates related to new safety risks for pharmaceutical products under the Regulatory Affairs department’s jurisdiction. It covers review, approval, artwork revision, and distribution of labeling materials including cartons, inserts, leaflets, and digital product information. The SOP excludes routine labeling changes unrelated to urgent safety concerns and does not apply to non-pharmaceutical products or investigational labeling unless specified by regulatory authorities.
Responsibilities
- Regulatory Affairs Team: Identification, evaluation, and communication of new risk information; coordination of labeling updates; liaison with regulatory authorities.
- Quality Assurance: Review and approval of labeling change documentation and compliance oversight.
- Labeling/Artwork Department: Preparation and verification of revised artwork and labeling materials.
- Manufacturing and Packaging: Implementation of updated labels on affected product batches.
- Pharmacovigilance: Providing new risk data and supporting labeling change justification.
- Document Control: Revision and archiving of controlled SOPs and change records related to labeling updates.
Accountability
The Head of Regulatory Affairs holds overall accountability for ensuring the SOP is effectively implemented, maintained, and reviewed periodically. This role is also responsible for escalation of compliance issues, timely communication with relevant stakeholders, and ongoing assessment of the SOP’s effectiveness.
Procedure
1. Initiation and Risk Identification: Upon identification of a new risk relevant to a marketed product, the Pharmacovigilance or Quality unit must immediately notify the Regulatory Affairs team. All risk information must be comprehensively documented and validated.
2. Risk Evaluation and Impact Assessment: Regulatory Affairs shall review the risk data to determine its impact on currently approved labeling. This includes assessing regulatory requirements, geographies affected, and urgency level. Cross-functional consultation with QA, Pharmacovigilance, and Manufacturing may be necessary.
3. Labeling Change Proposal and Approval: A detailed labeling change proposal shall be drafted outlining the necessary updates reflecting the new risk. This includes textual amendments, warnings, precautions, and any graphical changes. The proposal must be reviewed and approved by QA and the Head of Regulatory Affairs before proceeding.
4. Artwork Revision and Verification: Upon approval, the Labeling/Artwork team will update the labels and related documentation per the approved proposal. All artwork changes must undergo rigorous proofing and verification steps, including content accuracy, formatting compliance, and print readiness checks.
5. Regulatory Submission and Communication: Regulatory Affairs shall prepare and submit applicable regulatory dossiers or variation applications for the urgent change following local authority guidelines. Simultaneously, internal communication with Manufacturing, Packaging, Warehousing, and Distribution teams ensures awareness and preparedness for implementation.
6. Implementation and In-Process Controls: Manufacturing and Packaging units shall execute label printing and application on affected product batches under controlled conditions. Material issuance and batch release must verify the updated labeling’s correctness as per established procedures.
7. Documentation and Record Retention: All records pertaining to the risk identification, evaluation, labeling change proposal, approvals, artwork files, regulatory submissions, and implementation verification must be retained according to company policy and regulatory requirements.
8. Deviation Handling and Corrective Actions: Any deviations or non-compliances identified during the process must be documented, investigated, and corrective/preventive actions implemented promptly to maintain compliance.
9. Periodic Review and Effectiveness Check: The SOP and associated processes should be reviewed periodically (at least biennially) to ensure ongoing suitability, and updates made as necessary to reflect regulatory changes or process improvements.
This structured yet flexible approach ensures that urgent labeling updates are handled efficiently, meeting regulatory timelines, ensuring patient safety, and maintaining compliance within the pharmaceutical quality system.
Abbreviations
- QA – Quality Assurance
- GMP – Good Manufacturing Practice
- PV – Pharmacovigilance
- RA – Regulatory Affairs
- SOP – Standard Operating Procedure
- CAPA – Corrective and Preventive Action
- ICH – International Council for Harmonisation
Documents
The following documents are required specifically for managing urgent labeling updates following new risks:
- Urgent Labeling Change Request Form (Annexure-1)
- Labeling Change Approval Record (Annexure-2)
- Artwork Revision Checklist (Annexure-3)
References
- ICH Q9 Quality Risk Management
- EU GMP Annex 16 – Certification by a Qualified Person and Batch Release
- FDA Guidance on Labeling Changes for Safety Reasons
- Pharmaceutical Regulatory Authority Guidelines on Labeling Amendments
- Company Quality Management System Documentation
Version
1.0
Approval
| Prepared By | |
| Checked By | |
| Approved By |
Annexures
Annexure-1: Urgent Labeling Change Request Form
| Title | Urgent Labeling Change Request Form |
| Purpose | To document and initiate urgent labeling changes due to newly identified product risks. |
| Field | Details / Example |
|---|---|
| Request ID | ULCR-2026-001 |
| Product Name | ExamplePharma Pain Relief Tablets |
| Batch Number(s) | PRT-045678 |
| Date of Risk Identification | 10/04/2026 |
| Risk Description | New adverse event of severe allergic reaction reported post-marketing. |
| Urgency Level | High |
| Requested By | Pharmacovigilance Unit |
| Date of Request | 12/04/2026 |
| Supporting Documentation Attached | Safety report, risk evaluation summary |
| Signature of Requester | ………………………………………….. |
| Date | 12/04/2026 |
Annexure-2: Labeling Change Approval Record
| Title | Labeling Change Approval Record |
| Purpose | To document review and authorized approval of urgent labeling changes prior to artwork revision and implementation. |
| Field | Details / Example |
|---|---|
| Request ID | ULCR-2026-001 |
| Evaluation Summary | Reviewed risk data; confirmed necessity and compliance with regulatory requirements. |
| QA Approval | Approved |
| Date | 14/04/2026 |
| Regulatory Affairs Approval | Approved |
| Date | 14/04/2026 |
| Comments | Proceed with immediate artwork updates and submissions. |
| Signatures | …………………………………………. |
| Date | 14/04/2026 |
Annexure-3: Artwork Revision Checklist
| Title | Artwork Revision Checklist for Urgent Labeling Updates |
| Purpose | To ensure comprehensive verification of all labeling artwork revisions reflecting new risk information prior to print release. |
| Checklist Item | Status (Y/N) | Comments |
|---|---|---|
| Verify updated risk statements included | Y | Added warning on allergic reactions |
| Check font size and legibility | Y | Confirmed per standards |
| Confirm translation accuracy (if applicable) | N/A | English only batch |
| Proofread all textual changes | Y | No errors detected |
| Print color and quality check passed | Y | Approved by QA |
| Final approval for printing given | Y | Signed off on 15/04/2026 |
Revision History
| Revision Date | Revision No. | Revision Details | Reason for Revision | Approved By |
| 16/04/2026 | 1.0 | Initial issue | New SOP creation |